News | July 26, 2024
Piramal Pharma Q1 FY25 net loss narrows
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
This transaction is the third acquisition by three different Japanese players in this segment
Subscribe To Our Newsletter & Stay Updated
